The third wave of the corona has hit India, while Omicron has also aggravated the problem of many states. In addition to two doses of vaccine in the battle against the same omicron, the booster dose is considered very effective. The study on Tuesday found the booster dose of the covaxin of Bharat Biotech to be effective on omicron and delta variants. Now the good news has also come on the AstraZeneca booster dose. A new study conducted on Thursday found that an AstraZeneca booster dose produces a lot of antibodies against Vaxzevria omicrons.
Preliminary data from the same trial showed that the third dose of the corona, Vaxzevria, produces very good antibodies against omicron variants as well as other variants including beta, delta, alpha and gamma. It has to be given a booster dose. The drug manufacturer said that there has been an increased response among those vaccinated mRNA Vaxzevria or vaccines. He said he will soon hand over the data to regulators in view of the need for boosters all over the world.
This is encouraging news, as per Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group, new data from ongoing Astazeneca/Oxford vaccine trials has shown that three doses give good protection against Omicron. https://t.co/kiXbbooFxc— Adar Poonawalla (@adarpoonawalla) January 13, 2022
A lab study last month found that a three-dose course of Vaxjeveria was very effective against the rapidly spreading new variant. This is the first data released by the company on the booster dose after the trial. The AstraZeneca vaccine was developed by researchers at Oxford University. In India, this vaccine is being given in the name of Covishield, which is being made by the Serum Institute of India (SII). Its CEO Adar Poonawalla has also shared this data on his Twitter account and called it encouraging news. You can see this tweet here